Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic markers focused on oncology applications, utilizing Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology on Bio-Rad’s QX600 platform. Following regulatory clearance, Biodesix will manufacture and distribute dedicated specimen collection kits for the developed assays.

Diasorin (FTSE MIB: DIA) today announced the signing of a supplier agreement with Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services based in and serving the United States.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read technology, evaluating its performance on regions of the genome that traditional short-read technologies historically have not resolved. GeneDx's early results illustrate the ability of constellation to rapidly identify hard-to-detect variants implicated in rare disease. GeneDx's Director of Laboratory Innovation Joe Devaney will present on the company's early experiences with the constellation technology today at the American Society for Human Genetics (ASHG) Annual Meeting in Boston.

Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (Nasdaq: GRAL), today announced they have signed a binding Letter of Intent for a strategic collaboration to bring GRAIL's GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets. SCT and SEC have also agreed to invest $110 million into GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured, at a price of $70.05 per share of common stock.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

Roche announced its strategic collaboration with the Office for Attracting Strategic Enterprises (OASES) to accelerate healthcare innovation and strengthen Hong Kong's role as a leading hub for life sciences and medical technology in the Asia Pacific region.

Siemens Healthineers and the National University Hospital (NUH) Singapore have announced a strategic research collaboration to advance diagnostic solutions for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects nearly 40% of adults in Singapore — a prevalence that is higher than the global average of 30.05%.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recognized worldwide for accessible lab automation with more than 10,000 robotic systems deployed, today announced a multi-year collaboration. Together, BD and Opentrons will integrate robotic liquid-handling capabilities into BD single-cell multiomics instruments, automating critical experimental steps to accelerate and scale disease research and drug development.